Friday, 02 February 2018 19:25

Anticoagulation news items. Week commencing 29th January 2018

Low molecular weight heparin for prevention of venous thromboembolism in patients with lower‐limb immobilization

Cochrane Database of Systematic Reviews

Review (8 RCTs; n=3680) found moderate-quality evidence showing use of low molecular weight heparin in outpatients reduced DVT when immobilisation of lower limb was required vs. no prophylaxis/placebo. Low-quality evidence showed no clear differences in PE between groups.


Bypassing agent prophylaxis in people with hemophilia A or B with inhibitors

Cochrane Database of Systematic Reviews

Review of 4 RCTs (n=116) concludes prophylactic use of bypassing agents reduced bleeding events, joint bleeding events and number of affected joints. There was no evidence for improved quality of life amongst those who received prophylaxis vs those who received on-demand therapy.


Early use of tranexamic acid reduces bleeding more effectively

National Institute for Health Research Signal

Expert commentary is provided for a meta-analysis of 2 RCTs which found that in those with trauma bleeding or bleeding after birth, the survival benefits of tranexamic acid were estimated to decrease by 10% with every 15-minute delay in treatment.


Low molecular weight heparin for the prevention of severe preeclampsia: where next?

British Journal of Clinical Pharmacology

This review discusses the potential mechanisms of action of low molecular weight heparin for the prevention of severe preeclampsia, how to optimise the selection of high-risk women for participation in future trials, and the importance of trial standardisation.


Randomized Comparisons of Double-Dose Clopidogrel or Adjunctive Cilostazol versus Standard Dual Anti-platelet in Patients with High Post-Treatment Platelet Reactivity: Results of the CREATIVE Trial (Clopidogrel Response Evaluation and AnTi-platelet InterV


RCT (n=1078) found that in patients with low responsiveness to clopidogrel, as measured by thromboelastography, intensified antiplatelet strategies with adjunctive use of cilostazol improved clinical outcomes without increasing the risk of major bleeding.




The above records have been identified by UKMi and feature in the NICE Medicines Awareness Service. Further details on this service can be found at: